BioPharma Dive April 26, 2024
Prescription volume erosion is tracking with company forecasts, executives claimed, even as more insurers could exclude the branded drug.
Dive Brief:
- U.S. Humira sales fell 40% year over year during the first three months of 2024, to about $1.8 billion, as biosimilar copycats put pressure on AbbVie’s top-selling drug, the company said Friday in its first quarter earnings report.
- The declines were “in line” with what the company had anticipated for its inflammatory disease drug, AbbVie commercial chief Jeffrey Stewart said in a call with investors. Humira now faces 10 copycat competitors in the U.S., the first of which launched Jan. 31, 2023.
- Stewart said the company also expected a recent decision by CVS Health, whose pharmacy benefit manager...
Today's Sponsors
Today's Sponsor